Benjamin French1, Le Wang2, Bonnie Ky3, Jeffrey Brandimarto4, Anupam Basuray5, James C Fang6, Nancy K Sweitzer7, Thomas P Cappola8. 1. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania; Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania; Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Ohio Health: Riverside Methodist Hospital, Columbus, Ohio. 6. Division of Cardiovascular Medicine, University Hospital, Salt Lake City, Utah. 7. Division of Cardiology, University of Arizona, Tucson, Arizona. 8. Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: thomas.cappola@uphs.upenn.edu.
Abstract
BACKGROUND: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. METHODS AND RESULTS: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P < .001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P < .001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). CONCLUSIONS: Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.
BACKGROUND: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. METHODS AND RESULTS: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P < .001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P < .001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). CONCLUSIONS:Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.
Authors: Inder S Anand; Lloyd D Fisher; Yann-Tong Chiang; Roberto Latini; Serge Masson; Aldo P Maggioni; Robert D Glazer; Gianni Tognoni; Jay N Cohn Journal: Circulation Date: 2003-03-11 Impact factor: 29.690
Authors: Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Eduardo R Perna; Stella M Macin; Juan P Cimbaro Canella; Natalia Augier; Jorge L Riera Stival; Jorge R Cialzeta; Ariel E Pitzus; Edgar H Garcia; Ricardo Obregón; Mónica Brizuela; Alejandro Barbagelata Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Francoise Poirier; Francesco P Russo; John P Iredale; Christopher Haslett; Kenneth J Simpson; Tariq Sethi Journal: Proc Natl Acad Sci U S A Date: 2006-03-20 Impact factor: 11.205
Authors: David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman Journal: Antioxid Redox Signal Date: 2019-03-29 Impact factor: 8.401
Authors: Kathryn C B Tan; Ching-Lung Cheung; Alan C H Lee; Joanne K Y Lam; Ying Wong; Sammy W M Shiu Journal: Diabetologia Date: 2018-02-07 Impact factor: 10.122
Authors: Alexandra Dadarlat-Pop; Dana Pop; Lucia Procopciuc; Adela Sitar-Taut; Dumitru Zdrenghea; Gyorgy Bodizs; Raluca Tomoaia; Diana Gurzau; Florina Fringu; Silvana Susca-Hojda; Anca D Buzoianu Journal: Int J Gen Med Date: 2021-05-06